Artykuł w czasopiśmie
Brak miniatury
Licencja
CC-BY-NCCC-BY-NC - Uznanie autorstwa - Użycie niekomercyjne
 

COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS)

Uproszczony widok
dc.abstract.enWe conducted a prospective cohort study of 20 patients with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS group, median age seven years, 70% male) and 34 healthy controls without such a history (CONTROL group, median age eight years, 38% male) aged 5–12 years, to assess the immunogenicity of Pfizer-BioNTech COVID-19 mRNA BNT162b2 vaccine (Comirnaty®). Patients received two doses of COVID-19 mRNA BNT162b2 vaccine (10 ug/dose) 21 days apart. Pre-vaccine anti-S SARS-CoV-2 IgG antibodies were measured on the day of the first dose and at the median of 23 days after the second dose. The study was conducted during the COVID-19 wave dominated by the Omicron variant of the virus. Anti-NCP SARS-CoV-2 IgG antibodies were measured twice to evaluate incidents of infection during the study period. Pre-vaccine quantification of both types of antibodies allowed us to differentiate patients into COVID-19 naive and previously infected in order to compare hybrid immunity with vaccine-induced immunity. Before vaccination, anti-S IgG serum geometric mean concentration (GMC) was 61.17 BAU/ml in the PIMS group and 24.97 in the CONTROL group, while post-vaccination GMC was 3879.14 BAU/ml and 3704.87 BAU/ml, respectively, and did not significantly differ between the groups. Hybrid immunity (regardless of PIMS history) resulted in a higher concentration of SARS-CoV-2 anti-S antibodies after vaccination. Four (20%) of the children in the PIMS group and 11 (32%) in the CONTROL group got infected with SARS-CoV-2 during the study period, yet all of them asymptomatically, and this event has not significantly altered post-vaccination anti-S titers. In conclusion, COVID-19 vaccination was highly immunogenic in children, including those with a history of PIMS-TS; hybrid immunity overperforms vaccine-induced immunity in terms of serological response in children. However, vaccination effectiveness in preventing SARS-CoV-2 infections in children should be further evaluated.
dc.affiliationUniwersytet Warszawski
dc.contributor.authorMatkowska-Kocjan, Agnieszka
dc.contributor.authorBiela, Mateusz
dc.contributor.authorWójcik, Marta
dc.contributor.authorSzenborn, Filip
dc.contributor.authorLudwikowska, Kamila
dc.contributor.authorKursa, Miron
dc.contributor.authorSzenborn, Leszek
dc.contributor.authorZaryczański, Janusz
dc.contributor.authorPielka-Markiewicz, Ewa
dc.contributor.authorWielgos, Katarzyna
dc.contributor.authorPopiel, Aneta
dc.date.accessioned2024-01-24T20:54:22Z
dc.date.available2024-01-24T20:54:22Z
dc.date.copyright2023-05-14
dc.date.issued2023
dc.description.accesstimeAT_PUBLICATION
dc.description.financeŚrodki finansowe, o których mowa w art. 365 pkt. 2 ustawy
dc.description.number21
dc.description.versionFINAL_PUBLISHED
dc.description.volume41
dc.identifier.doi10.1016/J.VACCINE.2023.04.035
dc.identifier.issn0264-410X
dc.identifier.urihttps://repozytorium.uw.edu.pl//handle/item/103865
dc.identifier.weblinkhttp://dx.doi.org/10.1016/j.vaccine.2023.04.035
dc.languageeng
dc.pbn.affiliationbiological sciences
dc.relation.ispartofVaccine
dc.relation.pages3317-3327
dc.rightsCC-BY-NC
dc.sciencecloudnosend
dc.titleCOVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS)
dc.typeJournalArticle
dspace.entity.typePublication